Amphetamine-Induced Angiitis Leading to Renal Failure

Misleading Abdominal Computed Tomography in a Wasted Patient with Polyarteritis Nodosa

“…Since its description by Gocke et al (1970), an association between hepatitis B and PAN has been firmly established (Vertzman 1980) and it is known that one-quarter of patients with HBsAg positive PAN have no histological evidence of hepatitis or cirrhosis (Goddeau et al 1977). It is less well known that amphetamine abuse may also be associated with the occurrence of PAN-like vasculitis (Citron et al 1970, Rifkin 1977, Bostwick 1981. This association appears independent of HBsAg because although HBsAg might be expected in a high proportion of drug addicts, vasculitis indistinguishable from PAN can follow oral amphetamine abuse (Matick et al 1983) and develop in animals given the drug under sterile conditions (Rumbaugh et al 1971).…”

COVID-19 and Substance Use Disorders as Brain Diseases: Recommendations to a Comprehensive Healthcare Response. An International Society of Addiction Medicine (ISAM) Practice and Policy Interest Group Position Paper

“…Studies indicate that heroin users, especially PWID, suffer from nephropathy (Cunningham, Brentjens, Zielezny, Andres, & Venuto, 1980;do Sameiro Faria, Sampaio, Faria, & Carvalho, 2003;May, Helderman, Eigenbrodt, & Silva, 1986). Other studies confirm that individuals using amphetamine (Ginsberg, Ertzman, & Schmidt-Nowara, 1970;Rifkin, 1977), cocaine (Merigian & Roberts, 1987;Norris et al, 2001;Sharff, 1984), alcohol (De Marchi, Cecchin, Basile, Bertotti, Nardini, & Bartoli, 1993;Perneger, Whelton, Puddey, & Klag, 1999), and potent cannabis (Abodunde, Nakda, Nweke, & Veera, 2012;Gudsoorkar & Perez Jr, 2015) are more likely to suffer from renal failure. It might be logically concluded that people with a history of drug consumption are more prone to contract renal insufficiency when they are infected to COVID-19; however, there is not any revealing evidence so far.…”

Enfermedad renal crónica asociada a diacetilmorfina (heroína)

“…Los primeros informes de cambios renales secundarios al uso parenteral crónico de heroína, cocaína y anfetaminas aparecieron a finales de la década de 1960 y principios de la de 1970. 12,[39][40][41][42][43][44][45][46] Desde entonces, se ha visto un aumento exponencial en el número de investigaciones centradas en este fenómeno, lo que concuerda con un marcado crecimiento mundial del abuso de estas sustancias. 1,3 Aún no existe un modelo in vivo de la NAH, pero ha habido estudios in vitro que han dado alguna información acerca de la fisiopatología de este síndrome.…”